Steven C. Boggess

Steven C. Boggess

Auto-generated profile, based on publicly available information

Steven C. Boggess

Department of Chemistry, University of California, Berkeley, CA 94720

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
27 April 2022 in Nature Biomedical Engineering
Verified
Journal Article
Closed access
PDF file
NHNathaniel Huebsch
Nathaniel Huebsch
BCBerenice Charrez
Berenice Charrez
GNGabriel Neiman
Gabriel Neiman
BSBrian Siemons
Brian Siemons
SBSteven C. Boggess
Steven C. Boggess
KHKevin E. Healy
Kevin E. Healy

11 December 2020 in RSC Chemical Biology
Verified
Journal Article
Open access
PDF file
SBSteven C. Boggess
Steven C. Boggess
JLJulia R. Lazzari-Dean
Julia R. Lazzari-Dean
BRBenjamin K. Raliski
Benjamin K. Raliski
DMDong Min Mun
Dong Min Mun
ALAmy Y. Li
Amy Y. Li
EMEvan Miller
Evan Miller
Voltage imaging with fluorescent indicators offers a powerful complement to traditional electrode or Ca2+-imaging approaches for monitoring electrical activity.

29 March 2024 in Proceedings of the National Academy of Sciences
Verified
Journal Article
Open access
AGAnneliese M. M. Gest
Anneliese M. M. Gest
JLJulia R. Lazzari-Dean
Julia R. Lazzari-Dean
GOGloria Ortiz
Gloria Ortiz
SYSusanna K. Yaeger-Weiss
Susanna K. Yaeger-Weiss
SBSteven C. Boggess
Steven C. Boggess
EMEvan Miller
Evan Miller
Biological membrane potentials, or voltages, are a central facet of cellular life. Optical methods to visualize cellular membrane voltages with fluorescent indicators are an attractive complement to traditional electrode-based approaches, since imaging methods can be high throughput, less invasive, and provide more spatial resolution than electrodes. Recently developed fluorescent indicators for voltage largely report changes in membrane voltage by monitoring voltage-dependent fluctuations in fluorescence intensity. However, it would be useful to be able to not only monitor changes but also measure values of membrane potentials. This study discloses a fluorescent indicator which can address both. We describe the synthesis of a sulfonated tetramethyl carborhodamine fluorophore. When this carborhodamine is conjugated with an electron-rich, methoxy (-OMe) containing phenylenevinylene molecular wire, the resulting molecule, CRhOMe, is a voltage-sensitive fluorophore with red/far-red fluorescence. Using CRhOMe, changes in cellular membrane potential can be read out using fluorescence intensity or lifetime. In fluorescence intensity mode, CRhOMe tracks fast-spiking neuronal action potentials (APs) with greater signal-to-noise than state-of-the-art BeRST 1 (another voltage-sensitive fluorophore). CRhOMe can also measure values of membrane potential. The fluorescence lifetime of CRhOMe follows a single exponential decay, substantially improving the quantification of membrane potential values using fluorescence lifetime imaging microscopy (FLIM). The combination of red-shifted excitation and emission, mono-exponential decay, and high voltage sensitivity enable fast FLIM recording of APs in cardiomyocytes. The ability to both monitor and measure membrane potentials with red light using CRhOMe makes it an important approach for studying biological voltages.

27 May 2020 in bioRxiv
Verified
Preprint
Open access
PDF file
FLFelipe T. Lee-Montiel
Felipe T. Lee-Montiel
ALAlexander Laemmle
Alexander Laemmle
LDLaure Dumont
Laure Dumont
CLCaleb S. Lee
Caleb S. Lee
NHNathaniel Huebsch
Nathaniel Huebsch
KHKevin Healy
Kevin Healy
Microphysiological systems (MPSs) mimicking human organ function in vitro are an emerging alternative to conventional cell culture and animal models for drug development. Human induced pluripotent stem cells (hiPSCs) have the potential to capture the diversity of human genetics and provide an unlimited supply of cells. Combining hiPSCs with microfluidics technology in MPSs offers new perspectives for drug development. Here, the integration of a newly developed liver MPS with a cardiac MPS—both built with the same hiPSC line—to study drug-drug interaction (DDI) is reported. As a prominent example of clinically relevant DDI, the interaction of the arrhythmogenic gastroprokinetic cisapride with the fungicide ketoconazole was investigated. As seen in patients, metabolic conversion of cisapride to non-arrhythmogenic norcisapride in the liver MPS by the cytochrome P450 enzyme CYP3A4 was inhibited by ketoconazole, leading to arrhythmia in the cardiac MPS. These results establish functional integration of isogenic hiPSC-based liver and cardiac MPSs, which allows screening for DDI, and thus drug efficacy and toxicity, in the same genetic background.